Coach vs. Kors: Bat...
Health Care: Drugs
Discovery Laboratories Inc. (DSCO: NASDAQ)
$2.50 -0.02 | -0.79%
06/04/12 - 09:34 AM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -20.96M | -19.18M | -30.24M | -39.11M |
| Operating Gains/Losses | 45.00K | -16.00K | 0.00 | 110.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -574.00K | 391.00K | -817.00K | 1.35M |
| (Decrease) Increase In Other Current Liabilities | -259.00K | -2.18M | -1.71M | -1.77M |
| (Increase) Decrease In Other Working Capital | 174.00K | 4.00K | -1.00K | 498.00K |
| Other Non-Cash Items | -2.20M | -4.79M | 2.97M | 5.01M |
| Net Cash From Continuing Operations | -22.70M | -24.27M | -27.42M | -31.75M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -22.70M | -24.27M | -27.42M | -31.75M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 2.05M | 39.75M |
| Purchases of Property, Plant & Equipment | -106.00K | -101.00K | -147.00K | -632.00K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | -25.76M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 200.00K | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -106.00K | -101.00K | 2.10M | 13.36M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 896.00K |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 22.93M | 27.98M | 20.82M | 0.00 |
| Repayment of Long-Term Debt | -145.00K | -9.14M | -2.51M | -2.98M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 6.29M |
| Net Cash From Financing Activities | 22.78M | 18.84M | 18.31M | 4.21M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -22.00K | -5.53M | -7.00M | -14.18M |
Portfolios with DSCO
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- UserSmall Cap Stocks
- UserKJP Spring Break
- Userjet189 Portfolio 1
- Uservolume spike
- Usermoon_in_mood Portfolio 1
- UserDtech Portfolio 1
- UserLizann
- UserBNunnally Portfolio 1
- Usershaldar Portfolio 1
Latest DSCO Headlines from TheStreet
- 5 Stocks Under $10 Poised for Upside 04.27.12 | 11:04 am
- For Biotech Takeovers, Timing is Key 04.04.12 | 06:04 am
- For Biotech, 'Fail' is Making a Big Comeback 03.12.12 | 08:03 am
- Biotech Stock Mailbag: Oncothyreon, Amag, Keryx Hate Mail 03.09.12 | 05:03 am
- Market Preview: The Bulls Finally Blink (Correct) 03.06.12 | 10:03 pm
- Pandora, Discovery Labs: After-Hours Trading (Update 1) 03.06.12 | 08:03 pm
- The Next Big Thing in Biotech: Discovery Labs
03.02.12 | 06:03 am - Biotech Stock Mailbag: Cyclacel Fallout, the Skinny on Vivus, Celldex's Crash 03.02.12 | 05:03 am
- These Drugs Stocks Will Win FDA Approval 02.16.12 | 12:02 pm
- Play TheStreet's FDA Drug-Approval Contest 01.23.12 | 08:01 am
Press Releases for DSCO
- Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated With Reintubation In Premature Infants - PR Newswire 05.01.12 | 07:05 am
- Media Alert: Discovery Labs To Hold Conference Call To Discuss FDA Approval Of SURFAXIN® (lucinactant) - PR Newswire 03.07.12 | 07:03 am
- Discovery Labs Announces FDA Approval Of SURFAXIN® (lucinactant) For Prevention Of Respiratory Distress Syndrome - PR Newswire 03.06.12 | 04:03 pm
- Discovery Labs Signs Manufacturing Agreement For AFECTAIR® - PR Newswire 02.08.12 | 07:02 am
- Discovery Labs Cleared To Market AFECTAIR In U.S. - PR Newswire 02.02.12 | 07:02 am
- New Study Shows AFECTAIR® Significantly Improved Delivery Of Nitric Oxide Under Simulated Neonatal Ventilatory Conditions - PR Newswire 12.06.11 | 08:12 am
- Discovery Labs Releases New AFECTAIR⢠Performance Data Presented At The American Association For Respiratory Care Annual Meeting - PR Newswire 11.08.11 | 08:11 am
- New Study Shows Neonatologists And Parents Of NICU Infants Share Concern Regarding Newborn Exposure To Animal-Derived Medications - PR Newswire 10.18.11 | 07:10 am
- Discovery Labs Notified Of PDUFA Date For SURFAXIN® - PR Newswire 09.28.11 | 12:09 pm
- Discovery Labs Submits SURFAXIN® Complete Response To FDA - PR Newswire 09.06.11 | 07:09 am
Partner Headlines for DSCO
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch - Seeking Alpha 03.30.12 | 09:03 am
- Discovery Labs Down 17% After Public Offering Announcement - Benzinga 03.16.12 | 09:03 am
- Company News for March 8, 2012 - Corporate Summary - Zacks 03.08.12 | 10:03 am
- Discovery Labs Up 33% After Surfaxin Approved by the FDA - Benzinga 03.07.12 | 09:03 am
- Discovery Labs Announces FDA Approval of SURFAXIN for Prevention of Respiratory Distress Syndrome - Benzinga 03.06.12 | 04:03 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 11.15.11 | 09:11 am
- UPDATE 1-Discovery Labs' cystic fibrosis drug gets orphan status - Reuters 11.01.10 | 08:11 am
- UPDATE 1-Discovery Labs lung drug disappoints in mid-stage trial - Reuters 06.09.10 | 08:06 am
- FDA, Clinical Trial News: Discovery Labs, Hospira, Javelin Pharma - Seeking Alpha 05.20.10 | 06:05 am
